A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00683475
• Other study ID #: 13924
• Secondary ID: CP18-0601I4T-IE-
• Status: Completed
• Phase: Phase 2
• First received: May 19, 2008
• Last updated: October 7, 2014
• Start date: August 2008
• Est. completion date: September 2011

Study information

• Verified date: October 2014
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).

Description:

Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer-related death in men in the United States. Chemotherapy, either as a single agent or in combination, may lead to clinical response, pain control, and/or improved quality of life. Docetaxel is now the first-line standard therapy for AIPC. Mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for pain related to advanced Hormone Refractory Prostate Cancer (HRPC). Hormonal manipulations and docetaxel-based chemotherapy are often effective in metastatic prostate cancer; however, disease becomes refractory to these interventions in the majority of men. Although mitoxantrone continues to be a significant agent in the treatment of HRPC, there exists a need for more efficacious therapy in docetaxel-refractory- AIPC. Because of the potential contribution of Insulin Like Growth Factor Receptor (IGF-IR) and VEGFR-2 mediated pathways in prostate cancer pathogenesis, it is hypothesized that each of these biological agents in combination with mitoxantrone and prednisone will result in clinically meaningful activity in AIPC. Therefore, ImClone plans to conduct a randomized Phase 2 trial to assess the safety and efficacy of IMC-A12 or IMC-1121B (ramucirumab) in combination with mitoxantrone and prednisone in participants with AIPC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 138
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The participant has histologically-confirmed adenocarcinoma of the prostate

• The participant has radiographic evidence of metastatic prostate cancer (stage M1 or D2)

• The participant has prostate cancer unresponsive or refractory to hormone therapy (androgen-independent)

• The participant has had disease progression (clinical or radiographic) while receiving docetaxel, or within 120 days of receiving docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive significant benefit from additional docetaxel-based therapy, or was intolerant to therapy with this agent

• The participant must have evidence of progressive disease defined as at least one of the following;

1. Progressive measurable disease: using conventional solid tumor criteria

2. Bone scan progression: at least two new lesions on bone scan

3. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2

• The participant has a PSA = 2 ng/mL

• The participant has prior surgical or medical castration with a serum testosterone of <50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the participant must be willing to continue the use of LHRH agonists during protocol treatment

• The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2

• The participant has adequate hematologic function (absolute neutrophil count [ANC]=1500/uL, hemoglobin =9 g/dL, and platelets =100,000/uL)

• The participant has adequate hepatic function (bilirubin = 1.5 times the upper limit of normal (ULN), Aspartate Transaminase (AST) and Alanine Transaminase (ALT) = 3 times the ULN, or = 5 times the ULN if liver metastases are present)

• The participant has adequate renal function (creatinine = 1.5 x ULN or calculated creatinine clearance > 40 mL/min)

• The participant's urinary protein is = 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates = 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study

• The participant has adequate coagulation function (an international normalized ratio [INR] = 1.5 and a Partial Thromboplastin Time [PTT] = 5 seconds above the ULN [unless on oral anticoagulant therapy]). Participants receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (and if on warfarin have a therapeutic INR between 2 and 3)

• The participant has a fasting serum glucose level of < 160 mg/dL, or below the ULN

Exclusion Criteria:

• The participant has received more than one prior cytotoxic chemotherapy regimen for metastatic disease. (Participants who have had a treatment break followed by a second docetaxel-based regimen with subsequent disease progression are eligible.)

• The participant has received prior therapy with mitoxantrone for advanced prostate cancer (prior adjuvant therapy with mitoxantrone is permitted)

• The participant has a history of symptomatic congestive heart failure or has a pre-study echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) that is = 10% below the LLN

• The participant has received radiotherapy = 21 days prior to first dose of IMC-A12 or Ramucirumab

• The participant is receiving corticosteroids (dexamethasone, prednisone, or others) at a dose > 5 mg prednisone orally (PO) two times per day (BID) or equivalent. Participants receiving corticosteroids at higher doses may be eligible if their corticosteroid therapy is tapered to study levels (prednisone 5 mg PO BID) prior to first dose of study medication, without concomitant clinical deterioration

• The participant has known or suspected brain or leptomeningeal metastases

• The participant has uncontrolled or poorly controlled hypertension

• The participant has poorly controlled diabetes mellitus. Inclusion Criteria:

• The participant has histologically-confirmed adenocarcinoma of the prostate

• The participant has radiographic evidence of metastatic prostate cancer (stage M1 or D2)

• The participant has prostate cancer unresponsive or refractory to hormone therapy (androgen-independent)

• The participant has had disease progression (clinical or radiographic) while receiving docetaxel, or within 120 days of receiving docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive significant benefit from additional docetaxel-based therapy, or was intolerant to therapy with this agent

• The participant must have evidence of progressive disease defined as at least one of the following;

1. Progressive measurable disease: using conventional solid tumor criteria

2. Bone scan progression: at least two new lesions on bone scan

3. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2

• The participant has a PSA = 2 ng/mL

• The participant has prior surgical or medical castration with a serum testosterone of <50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the participant must be willing to continue the use of LHRH agonists during protocol treatment

• The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2

• The participant has adequate hematologic function (absolute neutrophil count [ANC]=1500/uL, hemoglobin =9 g/dL, and platelets =100,000/uL)

• The participant has adequate hepatic function (bilirubin = 1.5 times the upper limit of normal (ULN), aspartate transaminase [AST] and alanine transaminase [ALT]= 3 times the ULN, or = 5 times the ULN if liver metastases are present)

• The participant has adequate renal function (creatinine = 1.5 x ULN or calculated creatinine clearance > 40 mL/min)

• The participant's urinary protein is = 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates = 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study

• The participant has adequate coagulation function (an international normalized ratio [INR] = 1.5 and a partial thromboplastin time [PTT] = 5 seconds above the ULN [unless on oral anticoagulant therapy]). Participants receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (and if on warfarin have a therapeutic INR between 2 and 3)

• The participant has a fasting serum glucose level of < 160 mg/dL, or below the ULN

Exclusion Criteria:

• The participant has received more than one prior cytotoxic chemotherapy regimen for metastatic disease. (Participants who have had a treatment break followed by a second docetaxel-based regimen with subsequent disease progression are eligible.)

• The participant has received prior therapy with mitoxantrone for advanced prostate cancer (prior adjuvant therapy with mitoxantrone is permitted)

• The participant has a history of symptomatic congestive heart failure or has a pre-study echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) that is = 10% below the LLN

• The participant has received radiotherapy = 21 days prior to first dose of IMC-A12 or Ramucirumab

• The participant is receiving corticosteroids (dexamethasone, prednisone, or others) at a dose > 5 mg prednisone orally (PO) two times per day (BID) or equivalent. Participants receiving corticosteroids at higher doses may be eligible if their corticosteroid therapy is tapered to study levels (prednisone 5 mg PO BID) prior to first dose of study medication, without concomitant clinical deterioration

• The participant has known or suspected brain or leptomeningeal metastases

• The participant has uncontrolled or poorly controlled hypertension

• The participant has poorly controlled diabetes mellitus. Participants with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting < 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition

• The participant has a known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting < 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition

• The participant has a known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Biological:
• IMC-A12
IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.

Drug:
• Mitoxantrone
Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to = 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
• Prednisone
Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.

Biological:
• IMC-1121B (ramucirumab)
IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.

Locations

Country	Name	City	State
United States	ImClone Investigational Site	Abilene	Texas
United States	ImClone Investigational Site	Ann Arbor	Michigan
United States	ImClone Investigational Site	Atlanta	Georgia
United States	ImClone Investigational Site	Billings	Montana
United States	ImClone Investigational Site	Boca Raton	Florida
United States	ImClone Investigational Site	Buffalo	New York
United States	ImClone Investigational Site	Cedar Rapids	Iowa
United States	ImClone Investigational Site	Chicago	Illinois
United States	ImClone Investigational Site	Chlcago	Illinois
United States	ImClone Investigational Site	Cleveland	Ohio
United States	ImClone Investigational Site	Dallas	Texas
United States	ImClone Investigational Site	Durham	North Carolina
United States	ImClone Investigational Site	East Setauket	New York
United States	ImClone Investigational Site	Evanston	Illinois
United States	ImClone Investigational Site	Greenville	South Carolina
United States	ImClone Investigational Site	Houston	Texas
United States	ImClone Investigational Site	Houston	Texas
United States	ImClone Investigational Site	Knoxville	Tennessee
United States	ImClone Investigational Site	La Jolla	California
United States	ImClone Investigational Site	Madison	Wisconsin
United States	ImClone Investigational Site	Maryville	Illinois
United States	ImClone Investigational Site	Metairie	Louisiana
United States	ImClone Investigational Site	Nashville	Tennessee
United States	ImClone Investigational Site	New Haven	Connecticut
United States	ImClone Investigational Site	New York	New York
United States	ImClone Investigational Site	New York	New York
United States	ImClone Investigational Site	New York	New York
United States	ImClone Investigational Site	New York	New York
United States	ImClone Investigational Site	Philadelphia	Pennsylvania
United States	ImClone Investigational Site	Pittsburgh	Pennsylvania
United States	ImClone Investigational Site	Port St. Lucie	Florida
United States	ImClone Investigational Site	Rochester	Minnesota
United States	ImClone Investigational Site	Roseland	New Jersey
United States	ImClone Investigational Site	Seattle	Washington
United States	ImClone Investigational Site	Seattle	Washington
United States	ImClone Investigational Site	St Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite Progression-free Survival (cPFS)	Defined as the median time from randomization to the earliest of: Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST); Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of >=2 new lesions; New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression); Symptomatic progression (for participants without measurable disease); Other clinical events attributable to prostate cancer that require major interventions; or; Death from any cause; Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.	Randomization to composite progressive disease, up to 23.4 months	No
Secondary	Summary Listing of Participants Reporting Treatment-Emergent Adverse Events	Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.	Randomization to 36.3 months	Yes
Secondary	Time to Radiographic Evidence of Disease Progression	Time between date of randomization and earliest date of radiographic progression defined as either: Tumor progression by RECIST; Evidence of progression by bone scan; New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression).; Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy.	Randomization to date of radiographic progression, up to 36.3 months	No
Secondary	Prostate Specific Antigen (PSA) Response Rate	PSA response rate is defined as the percentage of participants with a decrease in PSA >= 50 percent from baseline.	Baseline up to data cut-off date (up to 36.3 months)	No
Secondary	Composite Progression-free Survival (cPFS) at 6-months	Data presented are the percentage of participants without disease progression at 6 months.; Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.	6 months	No
Secondary	Composite Progression-free Survival (cPFS) at 9-months	Data presented are the percentage of participants without disease progression at 9 months.; Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.	9 months	No
Secondary	Composite Progression-free Survival (cPFS) at 12-months	Data presented are the percentage of participants without disease progression at 12 months.; Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.	12 months	No
Secondary	Overall Survival (OS)	Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive.	First dose to death due to any cause up to 36.3 months	No
Secondary	Objective Response Rate (ORR)	Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions.; Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.	Baseline to date of progressive disease or death up to 36.3 months	No
Secondary	Maximum Concentration (Cmax) at Study Day 1	Maximum Concentration (Cmax) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 1	No
Secondary	Maximum Concentration (Cmax) at Study Day 15	Maximum concentration (Cmax) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 15	No
Secondary	Maximum Concentration (Cmax) at Study Day 16	Maximum concentration (Cmax) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 16	No
Secondary	Maximum Concentration (Cmax) at Study Day 30	Maximum concentration (Cmax) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 30	No
Secondary	Minimum Concentration (Cmin) at Study Day 1	Minimum concentration (Cmin) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 1	No
Secondary	Minimum Concentration (Cmin) at Study Day 15	Minimum concentration (Cmin) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 15	No
Secondary	Minimum Concentration (Cmin) at Study Day 16	Minimum concentration (Cmin) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 16	No
Secondary	Minimum Concentration (Cmin) at Study Day 30	Minimum concentration (Cmin) of Ramucirumab.; All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.	Day 30	No